

Substance use in youth at genetic and clinical high risk for psychosis

Carolyn M. Amir¹, Simon Kapler¹, Gil Hoftman¹, Leila Kushan¹, Jamie Zinberg¹, Kristin S. Cadenhead², Leda Kennedy², Barbara A. Cornblatt⁴, Matcheri Keshavan⁵, Daniel H. Mathalon⁶, Diana O. Perkins⁷, William Stone⁵, Ming T. Tsuang^{2,8}, Elaine F. Walker⁹, Scott W. Woods¹⁰, Tyrone D. Cannon¹¹, Jean Addington³, Carrie E Bearden^{1,12}

¹Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA, United States of America

²Department of Psychiatry, UCSD, San Diego, CA, United States of America

³Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

⁴Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States of America

⁵Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Mas

⁶Department of Psychiatry, UCSF, and SFVA Medical Center, San Francisco, CA, United States of America

⁷Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America

⁸Institute of Genomic Medicine, University of California, La Jolla, CA, United States of America

⁹Departments of Psychology and Psychiatry, Emory University, Atlanta, GA, United States of America

¹⁰Department of Psychiatry, Yale University, New Haven, CT, United States of America

¹¹Department of Psychology, Yale University, New Haven, CT, United States of America

¹²Department of Psychology, UCLA, Los Angeles, CA, United States of America

Abstract

Background: Elevated rates of alcohol, tobacco, and cannabis use are observed in both patients with psychotic disorders and individuals at clinical high risk for psychosis (CHR-P), and strong genetic associations exist between substance use disorders and schizophrenia. While individuals with 22q11.2 deletion syndrome (22qDel) are at increased genetic risk for psychosis, initial evidence suggests that they have strikingly low rates of substance use. In the current study, we aimed to directly compare substance use patterns and their neurobehavioral correlates in genetic and clinical high-risk cohorts.

Methods

Data on substance use frequency and severity, clinical symptoms and neurobehavioral measures were collected at baseline and at 12-month follow-up visits in two prospective longitudinal cohorts: participants included 89 22qDel carriers and 65 age and sex-matched typically developing (TD) controls (40.67% male, $M_{age}=19.26 \pm 7.84$ years) and 1288 CHR-P youth and 371 matched TD controls from the North American Prodrome Longitudinal Study-2 and 3 (55.74% male; $M_{age}=18.71 \pm 4.27$ years). Data were analyzed both cross-sectionally and longitudinally using linear mixed models.

Results

Controlling for age, sex, and site, CHR-P individuals had significantly elevated rates of tobacco, alcohol, and cannabis use relative to TD controls, whereas 22qDel had significantly lower rates. Increased substance use frequency and severity in CHR-P individuals was associated with increased positive psychosis symptom severity, dysphoric mood, social functioning, and IQ, while higher social anhedonia was associated with lower substance use frequency and severity, across all domains at baseline. These patterns persisted when we investigated these

relationships longitudinally over one-year. CHR-P youth exhibited significantly increased positive psychosis symptoms, dysphoric mood, social anhedonia, and IQ compared to 22qDel carriers, and significantly higher social functioning and lower rates of autism spectrum disorder (ASD) compared to 22qDel carriers, both at baseline and at one year follow-up.

Conclusions

Individuals at genetic and clinical high risk for psychosis have strikingly different patterns of substance use. Factors such as increased neurodevelopmental symptoms (lower IQ, higher rates of ASD) and poorer social functioning in 22qDel may help explain this distinction from substance use patterns observed in CHR-P individuals.

Introduction

Excessive substance use occurs at elevated rates in patients with psychotic disorders (Blanchard et al., 2000; Alvarez-Jimenez et al., 2012; Addington et al., 2014; Khokhar et al., 2018; Ward et al., 2018; Archibald 2019; Catthor & Dom, 2022; Correll et al., 2022) and cannabis use in particular has been suggested to play a role in the onset of psychosis (Arseneault et al., 2002; Caspi et al., 2005; Moore et al. 2007; Foti et al., 2010; Kuepper et al. 2011; Marconi et al., 2016; Mustonen et al., 2018; Hasin et al., 2020; Hasan et al., 2020). Patients with schizophrenia are 4.6 times more likely to use and abuse substances than the general population (Refier et al. 1990). Similar rates of hazardous substance use, ranging from 22% to over 50%, are reported for individuals at clinical high risk for psychosis (CHR-P)—individuals experiencing attenuated psychotic-like experiences preceding the onset of psychosis (Addington et al., 2014; van der Meer et al., 2012)—compared to typically developing controls (TD; Santesteban-Echarri et al., 2022; Stevenson et al., 2022; Farris et al., 2020; Buchy et al. 2015; Addington 2014). In contrast, a notable lack of substance use has been reported in people with chromosome 22q11.2 deletion syndrome (22qDel; Vingerhoets et al. 2019; Basset et al. 2003), one of the strongest genetic risk factors for psychosis (Rees et al. 2017; Marshall et al. 2017; Malhorta et al. 2012; Green et al. 2009; Chow et al. 2006).

The reasons for the substantially elevated rates of hazardous substance use in individuals with idiopathic psychotic disorders are not fully understood but are thought to be linked to the brain's dopaminergic pathways, associated with the reward properties of drugs and positive symptoms of psychosis (Khokhar 2018; Volkow 2009). Certain genetic factors lead to an increased risk of substance use and psychotic disorders, and genetic risk is thought to interact with environmental factors including the social environment (Moffitt et al., 2005; Fanous & Kendler, 2008; Henquet et al., 2008; Khokhar et al. 2018; Gillespie & Kendler, 2021). That individuals with 22qDel may need little or no environmental insult to develop psychosis is consistent with the liability threshold model; stronger genetic predisposition may 'tip the scales'

towards phenotypic expression of psychosis, even in the absence of environmental risk factors (McGue et al., 1983, Tsuang et al., 2001, McGuffin, 2004; Martin et al. 2014).

While not yet elucidated in 22qDel, neurobehavioral traits associated with hazardous substance use have been studied in CHR-P. In particular, positive symptom severity is greater in CHR-P who use illicit substances compared to CHR-P non-users and ultra high risk individuals have higher rates of unusual thought content and suspiciousness compared to ultra high risk non-users (Carney et al., 2017; van der Meer et al., 2012; Schifani et al., 2020). Relative to CHR-P without cannabis use, CHR cannabis users have significantly lower levels of social anhedonia (Gill et al., 2015; Kolliakou et al., 2015; Santesteban-Echarri et al., 2022). A proposed explanation for this inverse association is that CHR-P with lower levels of social anhedonia may tend to engage more with peers and seek substance use for social motives (Santesteban-Echarri et al., 2022). Further, CHR-P and individuals with first-episode psychosis report social engagement as a primary reason for cannabis use (Gill 2015; Gomez Perez 2017; Kolliakou 2015) and higher levels of social functioning are associated with elevated substance use rates in CHR-P (Author et al., 2012). While not yet studied in CHR-P, higher peer engagement has been found to be associated with increased risk for substance use particularly during adolescence (Keefe 1994; Kuther & Higgins-D'Alessandro 2003; Whitesell et al., 2013; Brooks-Russel et al. 2014), which has been theorized to be attributable to an increase in substance use accessibility with higher social engagement. Mood enhancement is also cited by CHR-P as a primary motivation for substance use seeking (Gill 2015), and while the association between mood and substance use has not yet studied in CHR-P, greater depression symptoms are associated with elevated substance use rates in adolescence (Rao 2006). CHR-P cannabis lifetime users have higher intelligence quotient (IQ) scores compared to non-users, which may be attributable to higher premorbid cognitive function (Ferraro et al., 2019).

To our knowledge, this is the first study examining substance use in CHR-P and 22qDel in parallel which offers a unique opportunity to contrast clinical and genetic factors underlying

hazardous substance use during adolescent development. Investigating factors associated with decreased rates of substance use in 22qDel could point to a protective phenomenon, with differential implications for prediction and treatment/prevention in subsets of individuals at high risk for psychosis. Here, we investigated rates of substance use in two prospective longitudinal cohorts, youth with CHR-P symptoms and youth with 22q11.2 deletions, as well as demographically-matched typically developing (TD) controls, with the hypothesis that CHR-P youth will have elevated rates of substance use relative to TD controls, both cross-sectionally and longitudinally over one year, whereas 22qDel participants will not. Second, we aimed to investigate the relationship of substance use to psychiatric symptoms and neurobehavioral traits. We predicted that better social functioning and higher IQ, as well as increased dysphoric mood and psychosis symptom severity would be associated with increased rates of substance use, while social anhedonia would be inversely related with substance use. We then examined differences in these measures between 22qDel carriers and CHR-P youth to elucidate the potential influence of social functioning, social anhedonia, dysphoric mood, psychosis symptom severity, and IQ on substance use patterns in this population.

Methods:

Participants

This study examined substance use over time in both individuals with molecularly confirmed 22q11.2 deletions (n = 89 22qDel, 45% male) and age and sex-matched typically developing controls (TD; n = 65, 46.15% male) and in CHR-P youth and age and sex-matched typically developing controls. CHR-P participants were recruited as part of the North American Prodromal Longitudinal Studies 2 (NAPLS 2; Addington 2012) and NAPLS 3 (Addington et al., 2022), designed to investigate predictors and mechanisms of transition to overt psychosis. This paper reports on 737 CHR-P youth (57.53% male) and 275 TD control subjects (50.18% male)

who completed substance use assessments. Use of the NAPLS 3 cohort in this study is intended to replicate our NAPLS 2 baseline findings in a population at higher risk for conversion to psychosis (at “enhanced” risk; 40% likelihood of psychosis conversion; Addington et al., 2022; Cannon et al., 2016) to test whether findings hold in an enhanced sample. NAPLS 3 participants include 551 “enhanced” CHR-P participants (56.99% male) and 96 TD control subjects (50% male). Detailed descriptions of the recruitment procedures and measures are reported elsewhere (Addington et al. 2012; Addington et al., 2022).

Individuals with 22qDel included in this study represent a subset of participants ascertained as part of an ongoing longitudinal study at the University of California, Los Angeles. Details of the recruitment and methods for this study are described elsewhere (Lin et al., 2020). Age and sex-matched TD participants were recruited from local communities via web-based advertisements and flyers/brochures in local schools, pediatric clinics, and other community sites. Exclusion criteria for all study participants included significant neurological or medical conditions (unrelated to 22qDel) that might affect brain structure or function, history of head injury with loss of consciousness, and insufficient fluency in English.

CHR individuals and TD controls were recruited for NAPLS studies, which were approved by the Institutional Review Boards of all eight NAPLS sites. Written informed consent, including parental consent, was obtained from all adult participants and parents/guardians of minors. The University of California, Los Angeles Institutional Review Board approved all study procedures and informed consent documents related to 22q11.2 CNV studies. Participants under the age of 18 years provided written assent, while their parent or guardian completed written consent in each study. Across both cohorts, we restricted our analyses to participants age 12 and older. As maximal data were available for the first two timepoints of the studies, longitudinal analyses included baseline visits and one-year follow-up visits.

Clinical Status

A summary of measures and timepoints analyzed in this study are presented in Table 1. The SIPS and the Scale for Assessment of Psychosis-Risk Syndromes (SOPS; McGlashan et al. 2010) were used to define CHR-P, rate dimensional psychosis-risk symptom severity and development of overt psychosis in both cohorts. Individual items were rated, and summary scores were determined for each domain (positive, negative, disorganized, and general symptoms). Total positive symptoms were defined as the sum of items in the positive symptom domain. Dysphoric mood was assessed via an item on the general symptom subscale, and social anhedonia as an item on the negative symptoms subscale. Full details regarding SIPS criteria, reliability and consensus procedures are described elsewhere (Addington et al. 2012; Addington et al., 2022). The SCID was used to establish *DSM-IV/V* Axis I diagnoses at baseline and follow-up for all participants, including ASD diagnosis. Clinical raters in both studies were experienced research clinicians; ratings and diagnoses were additionally validated via case consensus procedures (Addington et al., 2012; Addington et al., 2022; Lin et al., 2019). IQ in CHR-P was assessed by the Wechsler Abbreviated Scale of Intelligence (Wechsler 1999) and in 22qDel carriers was assessed by the Full-Scale Intelligence Quotient.

Table 1. Overview of assessments by sample and timepoint

Assessment	NAPLS 2 baseline	NAPLS 2 12 months	NAPLS 3 baseline	NAPLS 3 12 months	22qDel baseline	22qDel 12 months
Clinical Diagnosis*	SCID	SCID	SCID	SCID	SCID	SCID
Psychosis symptoms	SIPS/SCID	SIPS/SCID	SIPS/SCID	SIPS/SCID	SIPS/SCID	SIPS/SCID
Alcohol/drug use	AUS/DUS	AUS/DUS	AUS/DUS	-	SCID + CBCL	SCID + CBCL
Social functioning	Global functioning scale: Social	Global functioning scale: Social	Global functioning scale: Social	Global functioning scale: Social	Global functioning scale: Social	Global functioning scale: Social
Intelligence quotient (IQ)	WASI-2 FSIQ	WASI-2 FSIQ	WASI-2 FSIQ	WASI-2 FSIQ	WASI-2 FSIQ	WASI-2 FSIQ
Autism Spectrum Disorder	SCID	--	SCID	--	SCID/ADI/ADOS	--

**Modified SCID used across 22qDel and NAPLS studies includes an additional developmental disorders module (Foss-Feig et al., 2019)*

Substance Use

Substance use in NAPLS 2 and NAPLS 3 participants was assessed using the Alcohol Use Scale/Drug Use Scale (AUS/DUS; Drake et al. 1996) at all visits. Both severity (1 = abstinent, 2 = use without impairment, 3 = abuse, 4 = dependence) and frequency of substance use (0 = no use, 1 = once or twice per month, 2 = 3–4 times per month, 3 = 1–2 times per week, 4 = 3–4 times per week, 5 = almost daily) were collected for tobacco, alcohol, marijuana, cocaine, opiates, phencyclidine (PCP), amphetamines, methylenedioxy-methylamphetamine (MDMA), γ -hydroxybutyric acid (GHB), huffing (inhaling glue, other volatiles), hallucinogens, and other drugs. Frequency of tobacco use was the only item rated differently (0 = no use, 1 = occasionally, 2 = less than 10 times per day, 3 = 11–25 per day, 4 = more than 25 per day). Longitudinal group comparisons were conducted for NAPLS 2 data; baseline results were analyzed to test for replication in NAPLS 3, as control participants did not complete the AUS/DUS at follow-up in NAPLS 3. 22qDel and respective TD control participants were assessed at each timepoint via SCID interview for substance use/abuse within the past 6 months, and the Child Behavior Checklist (CBCL; Achenbach et al. 1991) was used to assess lifetime substance use or abuse, including alcohol, non-prescription drug use, and tobacco use. The CBCL was completed by parents of participants aged 12-18.

Social Functioning

The Global Functioning: Social scale was used to measure social functioning in both cohorts. Social functioning is calculated as highest level of social functioning in the past year. Developmentally appropriate, detailed descriptions are provided to illustrate the range of

functioning captured by each point on the scale, with lower scores indicating more impairment (Auther et al. 2006).

Analyses

Analyses were conducted in R 4.1.2 using statistical software package lme4 (Bates et al. 2015). We compared individuals with 22qDel to respective age and sex-matched TD controls, and CHR-P youth to a separate age and sex-matched TD control group (with TD controls as the reference groups). For NAPLS-2 and 22qDel cohorts, timepoints included intake visit and one-year follow-up visits, and longitudinal models included a group-by-time interaction. The use of substances other than alcohol, tobacco or cannabis was either minimal or absent in all samples; therefore, only alcohol, tobacco, and cannabis were considered for further statistical analysis. To determine whether CHR-P and 22qDel show different rates of substance use relative to TD controls, linear mixed models with substance use as the dependent variable and participant group as the independent variable were used to test for group differences in substance use (with controls as the reference group). We tested replication of NAPLS 2 results with NAPLS 3 baseline data, as substance use information was not collected longitudinally in NAPLS 3. Age, sex, and site were included covariates, and participant ID was included as the random effects term. FDR correction was applied within each model applied on effects of subject group.

To test relationships between substance use and clinical symptoms, linear mixed models with each symptom domain as dependent variable (DV) and substance use characterization as independent variable (IV) were tested for control and CHR-P participants at baseline in NAPLS 2 and NAPLS 3. In NAPLS 2, we tested relationships between baseline clinical symptoms and substance use at follow-up in CHR-P, additionally controlling for baseline substance use rates. Main effects of each model were FDR-corrected for multiple comparisons.

We then tested differences in clinical symptom measures between 22qDel participants and CHR-P to elucidate neurobehavioral traits influencing substance use patterns in this population (with 22qDel carriers as the reference group). Linear mixed models with substance use as the DV and participant group as the IV were used to test for differences in clinical symptom measures at baseline and longitudinally with participant age, sex, and site included as covariates. FDR correction was applied within each model applied on effects of subject group.

Results

Descriptives

Demographic variables at baseline are presented for each group in Table 2 and Table 3. There were significant differences in medication use between 22qDel carriers and TD controls, as well as between CHR-P and TD controls, such that TD controls had lower rates of medication use. In the CHR-P group there were significantly higher rates of Hispanic TD control participants compared to the 22qDel group and significantly higher rates of non-white participants.

Table 2: Baseline characteristics: 22qDel carriers and TD Controls

Baseline	Typically Developing Control Subjects	22q11.2 Deletion Carriers
N, total	61	89
Age, Years (SD), Age range ^b	17.18 (4.28); 12-28	20.17(10.18); 12-61
Males, n (%)	29(47.5%)	40(45%)
Non-white, n (%) ^a	22(39.3%)	8 (8.99%)
Hispanic ^a	17 (27.87%)	14 (15.73%)

Psychosis n (%) ^b	0(0.00%)	12(13.48%)
ASD, n (%) ^b	0(0.00%)	37(41.57%)
Alcohol use (%) ^a	10(16.39%)	3(3.37%)
Substance use (non-prescription) (%)	2(3.28%)	2(2.24%)
Tobacco use	2(3.28%)	1(1.12%)
Medication, n (%) ^b	2(3.28%)	41(46.07%)
Anti-Psychotics	0(0%)	15(16.85%)
Mood Stabilizers	0(0%)	13(14.6%)
Stimulants	1(1.54%)	5(5.62%)
Other Medication	1(1.54%)	8(9.00%)
No Medication	57(93.44%)	48(53.93%)

^aControl > 22qDel ($p < .05$)

^b22qDel > Control ($p < .05$)

Table 3. Baseline Characteristics: NAPLS 2 & 3 (CHR-P Subjects and TD Controls)

NAPLS 2 Baseline	TD Controls	CHR-P
N, total	275	737
Age, Years (SD), Age range ^a	19.76(4.68); 12-34	18.49(4.24); 12-35
Males, n (%)	138(50.18%)	424(57.53%)
Non-white, n (%)	125 (45.45%)	310(42.06%)
Hispanic	48 (17.45%)	138 (18.72%)
Medication, n (%) ^a	7(2.55%)	296(40.16%)
Anti-Psychotics	0(0%)	132(17.91%)
Mood Stabilizers	0(0%)	26(3.53%)

Stimulants	3(1.09%)	52(7.06%)
Other Medication	4(1.45%)	86(11.67%)
No Medication	262(95.27%)	441(59.84%)
NAPLS 3 Baseline	TD Controls	Clinical High Risk for Psychosis - Enhanced Subjects
N, total	96	551
Age, Years (SD), Age range	18.60(4.22); 12-30	18.42(4.04); 12-30
Males, n (%)	48 (50%)	314(56.99%)
Non-white, n (%) ^b	51(53.13%)	244(44.28%)
Hispanic	24 (24.00%)	125 (22.69%)
Medication, n (%) ^a	1(1.04%)	256 (46.46%)
Anti-Psychotics	0(0.0%)	114 (20.69%)
Mood Stabilizers	0(0.0%)	21 (3.81%)
Stimulants	1(1.04%)	40 (7.26%)
Other Medication	0(0.0%)	81 (14.7%)
No Medication	0(0.0%)	294 (53.36%)
^a CHR-P > Control ($p < .05$)		
^b Control > CHR-P ($p < .05$)		

Substance use at baseline and over time

Results of mixed models revealed that CHR-P had greater frequency and severity of both cannabis and tobacco use compared with controls both at baseline and longitudinally (Table 4). There was no statistical difference in alcohol use severity between controls and CHR-P (see Tables 4). All group differences in baseline substance use observed in NAPLS-2 replicated in NAPLS 3 (see Table S2). Controlling for tobacco use in cannabis models and psychotropic medication use in all substance use models did not affect results.

Table 4. Differences in Substance Use between CHR-P and TD control Groups in NAPLS 2

	Effect of Subject Group		Effect of Time		Group * Time Interaction	
	β	q-value	β	p-value	β	p-value
Cross-sectional						
Alcohol Use Frequency	-.052	.312	-	-	-	-
Alcohol Use Severity	-.027	.421	-	-	-	-
Cannabis Use Frequency	.348	<.001	-	-	-	-
Cannabis Use Severity	.384	<.001	-	-	-	-
Tobacco Use Frequency	.424	<.001	-	-	-	-
Tobacco Use Severity	.437	<.001	-	-	-	-
SIAS	1.23	<.001	-	-	-	-
GFS highest	-.539	<.001				
SAS	1.31	<.001	-	-	-	-
Positive Symptoms (SIPS)	1.869	<.001	-	-	-	-
Dysphoric Mood	1.518	<.001	-	-	-	-
Social Anhedonia	1.21	<.001	-	-	-	-
Longitudinal						

Alcohol Use Frequency	-.01	.757	.079	.006	-.034	.393
Alcohol Use Severity	.012	.752	.09	.004	-.057	.184
Cannabis Use Frequency	.160	<.001	.055	.061	-.026	.532
Cannabis Use Severity	.174	<.001	.051	.112	-.027	.538
Tobacco Use Frequency	.375	<.001	.029	.263	-.035	.331
Tobacco Use Severity	.207	<.001	.029	.26	-.036	.313
SIAS	.632	<.001	-.039	.131	-.15	<.001
GFS highest	-.580	<.001	.010	.668	.055	-.78
SAS	.718	<.001	-.027	.303	-.242	<.001
Positive Symptoms	.994	<.001	-.027	.192	-.353	<.001
Dysphoric Mood	.818	<.001	-.023	.408	-.295	<.001
Social Anhedonia	.629	<.001	-.016	.522	-.148	<.001

Table S1. Baseline substance use in NAPLS 2 and 3

NAPLS 2	Alcohol		Tobacco		Cannabis	
Baseline AUS/DUS assessment	CHR (n = 737)	Controls (n = 275)	CHR	Controls	CHR	Controls
Abstinent, N (%)	444 (60.24%)	134 (48.73%)	562 (76.26%)	255 (92.73%)	564 (76.53%)	246 (89.45%)

Use without impairment	272 (36.91%)	141 (51.27%)	163 (22.12%)	20 (7.27%)	145 (19.67%)	28 (10.18%)
Abuse	17 (2.31%)	0(0%)	5 (.68%)	0(0%)	26 (3.53%)	0(0%)
Dependence	4(.54%)	0(0%)	7 (.95%)	0(0%)	2 (.27%)	0(0%)

NAPLS 3	Alcohol		Tobacco		Cannabis	
Baseline AUS/DUS assessment	CHR (n = 551)	Controls (n = 96)	CHR	Controls	CHR	Controls
Abstinent, N (%)	344 (62.43%)	52 (53.17)	40 (7.26)	90 (93.75)	404 (73.32)	85 (88.54)
Use without impairment	191 (34.66)	43 (44.79)	99 (17.97)	6 (6.25)	110 (19.96)	11 (11.46)
Abuse	14 (2.54)	1 (1.04)	6 (1.09)	0 (0.0)	29 (5.26)	0 (0.0)
Dependence	2(.36%)	0 (0.0)	6 (1.09)	0 (0.0)	7 (1.27)	0 (0.0)

No 22qDel participants endorsed substance abuse or dependence in the past 6 months at baseline or follow-up timepoints. 22qDel carriers endorsed significantly lower rates of alcohol use than controls at both baseline ($b = -.217$, $q = .007$) and longitudinally ($b = -.336$, $q = .007$), and lower rates of non-prescription drug use at one-year follow-up ($b = -.284$, $q = .007$). Less than 4% of 22qDel carriers endorsed substance use at any timepoint, compared to 20% of TD controls endorsing substance use (See Table 2 for full results).

Relationships between psychosis symptom domains and substance use

Due to the lack of substance use in 22qDel participants, relationships between substance use and clinical symptoms could only be investigated in CHR-P (NAPLS 2 and NAPLS 3) participants (Tables 5 and S3). In both cohorts of CHR-P participants, positive symptoms were significantly positively associated only with cannabis use severity and frequency, and baseline positive symptom severity was positively associated with cannabis use severity but not frequency at follow-up in CHR-P participants (Table 5).

Dysphoric mood at baseline in CHR-P in NAPLS 2 was positively associated with cannabis use frequency and severity, tobacco use frequency and severity, and alcohol use severity (Table 5). In NAPLS 2, social anhedonia was inversely associated with substance use across all domains in CHR-P at baseline. Further, social anhedonia at baseline in CHR-P was inversely associated with substance use across all domains at one-year follow up. (Table 5). Baseline dysphoric mood in CHR-P in NAPLS 2 was positively associated with tobacco use frequency but no other substance use domain at follow-up. In NAPLS 3, dysphoric mood was positively associated with tobacco use frequency and severity in CHR-P and social anhedonia was inversely associated with substance use across all domains in CHR-P at baseline.

Relationship between social functioning and substance use

In NAPLS 2, alcohol use frequency and severity were both positively associated with social functioning in controls at baseline. In CHR-P, baseline social functioning was positively associated with substance use across all domains at baseline and was positively associated with all substance use domains at follow-up (Table 5). While the social functioning results in CHR-P replicated in NAPLS 3, alcohol use was not associated with social functioning in controls in NAPLS 3 (Table S3).

Table 5. Results of cross-sectional models in NAPLS 2

Cross-Sectional	Effect of Substance Use: Control Subjects		Effect of Substance Use: CHR-P Subjects	
	β	<i>q</i> -value	β	<i>q</i> -value
Positive Symptoms				
Alcohol Use Frequency	.041	.615	.044	.126
Alcohol Use Severity	-.015	.739	.018	.299
Cannabis Use Frequency	.129	.169	.096	.011
Cannabis Use Severity	.113	.187	.105	.010
Tobacco Use Frequency	.106	.226	.026	.251
Tobacco Use Severity	.052	.583	.064	.067
Dysphoric Mood				
Alcohol Use Frequency	.074	.071	.028	.065
Alcohol Use Severity	.046	.133	.068	.009
Cannabis Use Frequency	.211	<.001	.071	.009
Cannabis Use Severity	.125	.030	.083	.006
Tobacco Use Frequency	.112	.035	.073	.009
Tobacco Use Severity	.060	.107	.067	.011
Social Anhedonia				
Alcohol Use Frequency	-.075	.324	-.139	<.001
Alcohol Use Severity	-.051	.324	-.121	<.001
Cannabis Use Frequency	-.055	.324	-.092	.003
Cannabis Use Severity	-.056	.324	-.116	<.001
Tobacco Use Frequency	.014	.521	-.127	<.001
Tobacco Use Severity	.005	.552	-.164	<.001
IQ				
Alcohol Use Frequency	.131	.080	.199	<.001
Alcohol Use Severity	.109	.127	.169	<.001
Cannabis Use Frequency	-.030	.648	.086	.029
Cannabis Use Severity	.033	.627	.102	.010
Tobacco Use Frequency	-.018	.689	.016	.427

Tobacco Use Severity	.027	.653	.021	.393
GFS highest				
Alcohol Use Frequency	.187	.014	.178	<.001
Alcohol Use Severity	.199	.013	.173	<.001
Cannabis Use Frequency	.026	.603	.035	.106
Cannabis Use Severity	.049	.487	.066	.026
Tobacco Use Frequency	-.040	.545	.097	.004
Tobacco Use Severity	-.019	.637	.125	<.001

Table 6. Relationships between baseline clinical measures and substance use at one-year follow-up in NAPLS-2 CHR-P

Positive Symptoms	β	q-value
Alcohol Use Frequency	.007	.872
Alcohol Use Severity	.016	.715
Cannabis Use Frequency	.054	.262
Cannabis Use Severity	.095	.046
Tobacco Use Frequency	.007	.889
Tobacco Use Severity	-.009	.847
IQ		
Alcohol Use Frequency	.178	<.001
Alcohol Use Severity	.158	<.001
Cannabis Use Frequency	.118	.019
Cannabis Use Severity	.133	.008
Tobacco Use Frequency	-.006	.902
Tobacco Use Severity	0	.995
Dysphoric Mood		
Alcohol Use Frequency	0	.998
Alcohol Use Severity	0	.985
Cannabis Use Frequency	0	.996
Cannabis Use Severity	.027	.579
Tobacco Use Frequency	.120	.012
Tobacco Use Severity	.113	.019
Social Anhedonia		
Alcohol Use Frequency	-.166	<.001
Alcohol Use Severity	-.152	<.001
Cannabis Use Frequency	-.172	<.001
Cannabis Use Severity	-.185	<.001
Tobacco Use Frequency	-.221	<.001
Tobacco Use Severity	-.193	<.001
Anxiety Diagnosis		
Alcohol Use Frequency	-.009	.843
Alcohol Use Severity	-.033	.486
Cannabis Use Frequency	-.027	.591

Cannabis Use Severity	-.032	.521
Tobacco Use Frequency	-.009	.856
Tobacco Use Severity	.004	.940
GFS past year highest		
Alcohol Use Frequency	.145	<.001
Alcohol Use Severity	.109	.009
Cannabis Use Frequency	.028	.241
Cannabis Use Severity	.032	.222
Tobacco Use Frequency	.099	.021
Tobacco Use Severity	.102	.020

22qDel carriers vs. CHR-P: group differences in neurobehavioral symptoms

The CHR-P cohort (NAPLS 2) exhibited increased positive symptom severity, dysphoric mood and social anhedonia, as well as higher IQ scores compared to 22qDel carriers, both at baseline and longitudinally (Table 7). In contrast, 22qDel carriers showed lower global social functioning than CHR-P, both at baseline and longitudinally. 22qDel carriers exhibited significantly higher rates of autism spectrum disorder compared to CHR-P.

Table 7. Differences in neurobehavioral measures between 22qDel and NAPLS CHR subject groups

	Effect of Subject Group		Effect of Time		Group * Time Interaction	
	β	<i>q</i> -value	β	<i>p</i> -value	β	<i>p</i> -value
Cross-sectional						
Positive Symptoms	1.412	<.001	-	-	-	-
Dysphoric Mood	1.010	<.001	-	-	-	-
Social Anhedonia	.357	<.001	-	-	-	-
SCID: ASD	-2.171	<.001	-	-	-	-
GFS highest	.398	<.001	-	-	-	-
IQ	1.521	<.001	-	-	-	-

S2. Differences in Substance Use between CHR-P and TD control Groups in NAPLS 3

	Effect of Subject Group		Effect of Time		Group * Time Interaction	
	β	<i>p</i> -value	β	<i>q</i> -value	β	<i>p</i> -value
Cross-sectional						
Alcohol Use Frequency	-.082	.136	-	-	-	-
Alcohol Use Severity	-.088	.129	-	-	-	-
Cannabis Use Frequency	.297	.003	-	-	-	-
Cannabis Use Severity	.380	<.001	-	-	-	-
Tobacco Use Frequency	.299	.002	-	-	-	-
Tobacco Use Severity	.343	<.001	-	-	-	-
GFS	-1.416	<.001	-	-	-	-
Positive Symptoms (SIPS)	2.37	<.001	-	-	-	-
Negative Symptoms	1.543	<.001	-	-	-	-
Disorganized Symptoms	1.377	<.001	-	-	-	-
General Symptoms	1.695	<.001	-	-	-	-
Dysphoric Mood	1.720	<.001	-	-	-	-
Social Anhedonia	1.216	<.001	-	-	-	-

S3. NAPLS 3 Relationships between neurobehavioral measures and substance use in TD controls and CHR-P

Cross-Sectional	Effect of Substance Use: Control Subjects		Effect of Substance Use: CHR-P Subjects	
	β	<i>q</i> -value	β	<i>q</i> -value
Positive Symptoms				
Alcohol Use Frequency	.147	.072	-.033	.159

Alcohol Use Severity	<.001	.423	-.054	.083
Cannabis Use Frequency	.165	.074	.137	.002
Cannabis Use Severity	.105	.186	.096	.024
Tobacco Use Frequency	.363	<.001	.026	.180
Tobacco Use Severity	.481	<.001	.064	.051
GFS	β	<i>q</i> -value	β	<i>q</i> -value
Alcohol Use Frequency	.033	.391	.169	<.001
Alcohol Use Severity	.021	.984	.213	<.001
Cannabis Use Frequency	-.047	.987	.140	<.001
Cannabis Use Severity	.028	.987	.146	<.001
Tobacco Use Frequency	-.019	.989	.116	<.001
Tobacco Use Severity	-.01	.988	.061	<.001
Dysphoric Mood				
Alcohol Use Frequency	.044	.163	.047	.088
Alcohol Use Severity	.049	.149	.054	.071
Cannabis Use Frequency	.042	.181	.04	.093
Cannabis Use Severity	.023	.289	.02	.155
Tobacco Use Frequency	.081	.067	.084	.018
Tobacco Use Severity	.113	.017	.119	.003
Social Anhedonia				
Alcohol Use Frequency	-.059	.214	-.129	<.001
Alcohol Use Severity	-.110	.163	-.160	<.001
Cannabis Use Frequency	.201	.087	-.112	<.001
Cannabis Use Severity	.120	.164	-.141	<.001
Tobacco Use Frequency	-.081	.202	-.110	<.001
Tobacco Use Severity	-.062	.529	-.101	<.001

IQ				
Alcohol Use Frequency	.089	.338	.053	.055
Alcohol Use Severity	.101	.296	.055	.055
Cannabis Use Frequency	-.032	.762	-.065	.055
Cannabis Use Severity	-.032	.748	-.056	1
Tobacco Use Frequency	.014	.892	-.081	.055
Tobacco Use Severity	.057	.593	-.045	1
GFS highest				
Alcohol Use Frequency	.350	.004	.219	<.001
Alcohol Use Severity	.156	.198	.239	<.001
Cannabis Use Frequency	-.069	.524	.180	<.001
Cannabis Use Severity	.006	.956	.194	<.001
Tobacco Use Frequency	.089	.424	.121	<.001
Tobacco Use Severity	.125	.260	.091	<.001

Discussion

Our study represents, to our knowledge, the first direct comparison of substance use patterns and neurobehavioral correlates in youth at clinical and genetic high risk for psychosis. Specifically, we compared youth with 22q11.2 deletions (22qDel) to a clinically/behaviorally defined high-risk cohort (CHR-P youth), and found support for extremely low rates of substance use in 22qDel, but elevated rates of substance use in CHR-P youth, relative to TD controls. These results suggest that despite conferring elevated risk for psychosis (Olsen et al., 2018), the 22q11.2 deletion appears to be protective against initiating and/or continuing substance use. We then tested cross-sectional and longitudinal associations between substance use and neurobehavioral traits in CHR-P youth and found broadly that increased severity of positive psychosis symptoms and dysphoric mood, as well as better social functioning and higher IQ,

were associated with greater substance use frequency and severity. In contrast, greater social anhedonia was associated with significantly lower substance use, across domains. These patterns persisted when we investigated these relationships longitudinally over one-year. Finally, we directly compared these neurobehavioral measures in 22qDel carriers and CHR-P youth and found that CHR-P youth exhibited significantly increased positive psychosis symptoms, dysphoric mood, social functioning, and IQ compared to 22qDel carriers, but significantly lower current social anhedonia as well as lower rates of ASD compared to 22qDel carriers.

This work expands upon prior studies reporting elevated rates of substance use in individuals at high risk for psychosis (Santesteban-Echarri et al., 2022; Farris et al., 2020; Buchy et al. 2015; Addington et al., 2014) by examining associated neurobehavioral factors both cross-sectionally and longitudinally and in parallel with a population at genetically high risk for psychosis. Substances of misuse directly or indirectly activate the mesolimbic dopamine pathway, which is associated with the reward properties of drugs and positive symptoms of schizophrenia (Volkow et al. 2009). An array of dopaminergic abnormalities have been reported in CHR-P populations, including alterations in midbrain and striatal responses to reward assessed via functional neuroimaging studies, and elevated dopamine synthesis, storage, and release, observed in positron emission tomography and single photon emission computed tomography studies (for a review see Howes et al. 2022). In addition, CHR-P individuals display impaired reward processing associated with abnormal striatal activity during task performance (Karcher et al., 2016; Walz et al., 2015), related to symptom severity. Research on 22qDel mesolimbic differences using neuroendocrine and peripheral dopaminergic markers has revealed dopaminergic abnormalities (Boot et al. 2008), along with deficits in pleasure responses and reduced activation in medial frontal areas during reward anticipation (van Duin et al. 2016; Dubourg et al. 2016). Our study supports a body of work indicating that elevated rates of

cannabis use in individuals at high risk for psychosis are related to positive psychosis symptom severity, which may be mediated by alterations in these reward-related pathways (for reviews, see Farris et al., 2020, and Gunasekera et al., 2022), while there is mixed evidence on the association between alcohol or tobacco use and positive psychosis symptoms (Addington et al., 2014). By contrast, positive symptom severity was significantly lower in 22qDel carriers.

CHR-P youth displayed significantly better social functioning and reduced rates of ASD compared to 22qDel carriers, and social functioning was positively associated with substance use, both at baseline and longitudinally, within CHR-P. These results are consistent with previous descriptions of withdrawn behavior and problems with peer social interaction in 22qDel carriers (Swillen & McDonald-McGinn 2015), as well as with a previous single-site study finding higher levels of social functioning associated with elevated substance use rates in CHR-P (Author et al., 2012). CHR-P individuals report social engagement as a primary reason for substance use (Gill et al., 2015; Gomez-Perez et al., 2017; Kolliakou et al., 2015). It has been hypothesized that social skills facilitate drug acquisition in individuals with psychotic disorders such that poorer social skills make illicit substances more difficult to obtain (Mueser et al., 2000; Compton et al. 2004), especially where there are legal barriers (Rais et al. 2008). Higher peer engagement has been found to be associated with increased risk for substance use particularly during adolescence (Keefe 1994; Kuther & Higgins-D'Alessandro 2003; Whitesell et al., 2013; Brooks-Russel et al. 2014). In addition to high rates of ASD (Lin et al., 2019), social phobia is overrepresented in 22qDel (Dekker & Koot 2003) and may represent a barrier to drug acquisition and use. That social functioning is significantly lower in 22qDel carriers compared to CHR-P youth may in fact represent a protective factor against hazardous substance use for 22qDel carriers.

In both NAPLS 2 and NAPLS 3 CHR cohorts, dysphoric mood was positively associated with all substance use domains at baseline and predicted elevated tobacco use rates at follow up. This is consistent with previous reports of CHR-P individuals citing mood enhancement as motivation for seeking cannabis (Gill et al., 2015; Green 2004; Spencer 2002). That 22qDel carriers had significantly lower dysphoric mood compared to CHR-P youth may indicate that while mood enhancement is a primary motivation for drug-seeking in CHR-P individuals, this motive may not be as strong for 22qDel carriers.

Social anhedonia in CHR-P was significantly inversely correlated with substance use at baseline and predicted decreased substance use at follow-up. This supports previous findings that CHR-P cannabis users have significantly lower levels of social anhedonia compared to CHR-P non-users, proposed to be explained by lower social anhedonia driving peer engagement and substance-seeking for social motives (Gill et al., 2015; Kolliakou et al., 2015; Santesteban-Echarri et al., 2022). That levels of social anhedonia were lower in 22qDel carriers compared to CHR-P may indicate that lower rates of social anhedonia in 22qDel may not be driving peer engagement and substance use in the same way as for CHR-P individuals. Lower social functioning and elevated rates of ASD in 22qDel carriers may again serve as a protective barrier to facilitating peer engagement and substance use and acquisition. While a relationship between psychosis symptoms, specifically increased grandiosity and lowered social anhedonia, and cannabis use have been reported in NAPLS 3 (Santesteban-Echarri et al., 2022), our work expands upon these findings by focusing specifically on the enhanced sample of participants and investigating alcohol and tobacco use. Results broadly replicated in our enhanced CHR-P sample (NAPLS 3), providing support that these findings hold in a population at especially high risk for psychosis.

Consistent with previous literature (Ferraro et al., 2019), here we also found that the likelihood of substance use increased with higher IQ within the CHR-P group. IQ scores in CHR-P youth were, on average, significantly higher compared to those of 22qDel carriers. While we could not test the relationship between IQ and substance use in 22qDel patients given the minimal substance use reported in our cohort, a previous study reported substance use increased with higher IQ scores in 22qDel carriers (Vingerhoets et al., 2019). This prior work speculated as an explanation for these findings that individuals with more severe intellectual disability (ID) are more likely to be cared for or protected by their family members or institutions providing supervision. Substance use rates are relatively low in individuals with idiopathic ID compared to TD individuals, similarly to 22qDel; however, compared to individuals with substance use disorders (SUD) without ID, individuals with ID and SUD are less likely to receive treatment or to remain in treatment (Chapman & Wu, 2012; van Duijvenbode et al., 2015). Some variables found to influence substance use in individuals with ID include social pressure and the desire to increase social inclusion and overcome loneliness (Christian. & Poling, 1997; Degenhardt, 2000; Kalyva, 2007). Future work should investigate whether 22qDel carriers who do have hazardous substance use patterns are undertreated.

The current study has several important clinical implications. That 22qDel, despite conferring increased genetic risk for psychosis, is protective against problematic substance use offers insight into behavioral risk factors that can be targeted for intervention in individuals at CHR-P. Drugs of abuse can contribute to the positive symptoms of psychosis, and people with any substance use disorder have an earlier age of schizophrenia onset (for a review, see Hunt et al. 2018). Cannabis in particular can be a contributory risk factor for psychotic disorder, and animal models show that the developing brain is susceptible to cannabis-induced brain morphological and circuitry changes (Hall & Degenhardt 2008; Realini et al. 2011). As cannabis legalization becomes more prevalent, it is important to identify avenues for behavioral intervention for CHR-

P as access increases. Our findings suggest the importance of neurobehavioral risk factors and social context in influencing substance use in CHR-P, and abstinence in 22qDel, pointing to an intervention that targets social influence in disrupting the initiation and continuation of substance use. Strengths of this study include the large sample of individuals at CHR-P and the sample of participants with 22qDel, a relatively rare disorder. Adolescence and young adulthood are crucial developmental periods for studying the relationship between substance use and psychosis (e.g. Henquet et al. 2008); our study provides longitudinal insight into the progression of clinical symptoms and behavioral trajectories during neurodevelopment, whereas many previous studies utilize cross-sectional designs. Previous literature has focused primarily on the relationship between cannabis use and schizophrenia rather than psychosis spectrum disorders, and mixed findings have been attributed to differences in the temporal relationship between onset of cannabis use and onset of psychosis (Machielsen et al. 2010). Most previous studies on substance use in psychiatric populations lack details on the severity and frequency of use, and often conflate types of substance use, and very few include a healthy comparison group.

This study also has several important limitations. A majority of NAPLS data was collected pre-legalization of marijuana in the United States, and rates of substance use in this sample may become greater in regions where marijuana is legalized. Details on cannabis use including type of cannabis, dose, and whether cannabidiol was also consumed were not collected. Urine toxicology data would have also provided important biological information on cannabis use in the sample. Future directions include studying cannabis consumption at a finer level of detail. In NAPLS 2 there were few “abuse” and “dependence” occurrences recorded for substance use, and this may limit an ability to detect a contribution of heavy substance use to psychotic transition and/or clinical outcome. Demands of the NAPLS studies may also have deterred heavier substance users from participating, which may have biased our samples. While

psychotropic medication usage rates are comparable amongst CHR-P and 22qDel patients and controlling for medication use did not affect our results, other medical issues specific to 22qDel may also explain decreased substance use. Extremely low rates of substance use in 22qDel carriers rendered this study underpowered to detect associations between substance use and neurobehavioral traits in 22qDel carriers.

In conclusion, we found that despite higher rates of substance use in CHR-P individuals compared with controls, individuals with 22qDel, although at increased risk for psychosis, had markedly lower prevalence of substance use relative to TD controls. As this is the first study to investigate neurobehavioral traits underlying substance use patterns in CHR-P compared to 22qDel carriers, more research is needed into other factors such as environmental risk that may interplay with genetic factors to confer this effect. 22qDel could be a valuable model to study genetic factors in addition to behavioral factors underlying substance use in the general population.

References

Achenbach, T. M., & Edelbrock, C. (1991). Child behavior checklist. Burlington (Vt), 7, 371-392.

Addington J, Cadenhead KS, Cornblatt, BA, et al. (2012). North American Prodrome Longitudinal Study (NAPLS 2): Overview and recruitment. *Schizophrenia Research*. 142(1-3):77-82.

Addington, J., Case, N., Saleem, M. M., Auther, A. M., Cornblatt, B. A., & Cadenhead, K. S. (2014). Substance use in clinical high risk for psychosis: a review of the literature. *Early Intervention in Psychiatry*, 8(2), 104-112.

Addington, J., Liu, L., Brummitt, K., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., ... & Cannon, T. D. (2022). North American prodrome longitudinal study (NAPLS 3): methods and baseline description. *Schizophrenia research*.

Alvarez-Jimenez, M., Priede, A., Hetrick, S. E., Bendall, S., Killackey, E., Parker, A. G., ... & Gleeson, J. F. (2012). Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. *Schizophrenia research*, 139(1-3), 116-128.

Antshel, K. M., Fremont, W., Roizen, N. J., Shprintzen, R., Higgins, A. M., Dhamoon, A., & Kates, W. R. (2006). ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome. *Journal of the American Academy of Child & Adolescent Psychiatry*, 45(5), 596-603.

Archibald, L., Brunette, M. F., Wallin, D. J., & Green, A. I. (2019). Alcohol use disorder and schizophrenia or schizoaffective disorder. *Alcohol research: current reviews*, 40(1).

Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *Bmj*, 325(7374), 1212-1213.

Auther AM, Smith CW, Cornblatt BA. Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker Hillside Hospital, 2006.

Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA (2012).

Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. *Psychological Medicine* 42, 2485–2497.

Banyal, N., Bhattacharyya, D., & Yadav, P. (2018). Study to determine the prevalence of substance use and factors associated with it, in first-episode of psychosis. *Industrial Psychiatry Journal*, 27(2), 264.

Barkus, E., & Murray, R. M. (2010). Substance use in adolescence and psychosis: clarifying the relationship. *Annual review of clinical psychology*, 6(1), 365-389.

Barnes, TRE, Mutsatsa, SH, Hutton, SB, Watt, HC, Joyce, EM. Comorbid substance use and age at onset of schizophrenia. *Br J Psychiatry* 2006; 188(3): 237–42.

Bassett, A. S., Chow, E. W., AbdelMalik, P., Gheorghiu, M., Husted, J., & Weksberg, R. (2003). The schizophrenia phenotype in 22q11 deletion syndrome. *American Journal of Psychiatry*, 160(9), 1580-1586

Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw.* 2015;67:148.

Birmaher, B., Khetarpal, S., Brent, D., Cully, M., Balach, L., Kaufman, J., & Neer, S. M. (1997). The screen for child anxiety related emotional disorders (SCARED): Scale construction and

psychometric characteristics. *Journal of the American Academy of Child & Adolescent Psychiatry*, 36(4), 545-553

Blanchard, J. J., Brown, S. A., Horan, W. P., & Sherwood, A. R. (2000). Substance use disorders in schizophrenia: review, integration, and a proposed model. *Clinical psychology review*, 20(2), 207-234

Boot, E., Booij, J., Zinkstok, J., Abeling, N., De Haan, L., Baas, F., ... & Van Amelsvoort, T. (2008). Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. *Neuropsychopharmacology*, 33(6), 1252-1258.

Brooks-Russell, A., Simons-Morton, B., Haynie, D., Farhat, T., & Wang, J. (2014). Longitudinal relationship between drinking with peers, descriptive norms, and adolescent alcohol use. *Prevention science*, 15(4), 497-505.

Buchy, L., Cannon, T.D., Anticevic, A. et al. Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. *BMC Psychiatry* 15, 276 (2015).
<https://doi.org/10.1186/s12888-015-0656-x>

Buckner, J. D., Heimberg, R. G., Ecker, A. H., & Vinci, C. (2013). A biopsychosocial model of social anxiety and substance use. *Depression and anxiety*, 30(3), 276-284.

Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. *Archives of General Psychiatry* 65, 28–37.

Cannon, T. D., Yu, C., Addington, J., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., ... & Kattan, M. W. (2016). An individualized risk calculator for research in prodromal psychosis. *American Journal of Psychiatry*, 173(10), 980-988.

Carney, R., Cotter, J., Firth, J., Bradshaw, T., Yung, A.R., 2017. Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. *Acta Psychiatr. Scand.* 136 (1), 5–15.

Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. *Biological Psychiatry* 57, 1117–1127.

Catthoor, K., & Dom, G. (2022). Psychotic Disorders and Substance Abuse Comorbidity: Characteristics and Treatment. In *Psychosis and Personality Disorders* (pp. 57-73). Springer, Cham.

Chapman, S. L. C., & Wu, L. T. (2012). Substance abuse among individuals with intellectual disabilities. *Research in developmental disabilities*, 33(4), 1147-1156

Christian, L., & Poling, A. (1997). Drug abuse in persons with mental retardation: A review. *American Journal on Mental Retardation*, 102(2), 126-136.

Chow EWC, Watson M, Young DA, Bassett AS. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. *Schizophrenia Research*. 2006;87:270–8. 22.

Compton, M. T., Furman, A. C., & Kaslow, N. J. (2004). Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. *Schizophrenia research*, 71(1), 61-64.

Correll, C. U., Bitter, I., Hoti, F., Mehtälä, J., Wooller, A., Pungor, K., & Tiihonen, J. (2022). Factors and their weight in reducing life expectancy in schizophrenia. *Schizophrenia Research*, 250, 67-75.

Degenhardt, L. (2000). Interventions for people with alcohol use disorders and an intellectual disability: A review of the literature. *Journal of Intellectual and Developmental Disability*, 25(2), 135-146.

Dekker, M. C., & Koot, H. M. (2003). DSM-IV disorders in children with borderline to moderate intellectual disability. I: Prevalence and impact. *Journal of the American Academy of Child & Adolescent Psychiatry*, 42(8), 915-922.

Drake RE, Mueser K, McHugo G (1996). Clinical rating scales. In *Outcomes Assessment in Clinical Practice* (ed. L. Sederer and B. Dickey), pp. 113–116. Williams and Wilkins: Baltimore.

Dubourg, L, Schneider, M, Padula, M, Eliez, S. Reward Processes, White Matter Pathways of the Reward System and Negative Symptoms in 22q11DS. *Organization for Human Brain Mapping*, 2016.

Farris, M. S., Shakeel, M. K., & Addington, J. (2020). Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. *Social Psychiatry and Psychiatric Epidemiology*, 55(5), 527-537.

Fanou, A. H., & Kendler, K. S. (2008). Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. *Current Psychiatry Reports*, 10(2), 164-170.

Foss-Feig, J. H., Velthorst, E., Smith, L., Reichenberg, A., Addington, J., Cadenhead, K. S., ... & Bearden, C. E. (2019). Clinical profiles and conversion rates among young individuals with autism spectrum disorder who present to clinical high risk for psychosis services. *Journal of the American Academy of Child & Adolescent Psychiatry*, 58(6), 582-588.

Foti, D. J., Kotov, R., Guey, L. T., & Bromet, E. J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *American Journal of Psychiatry*, 167(8), 987-993.

Fung, W. L. A., McEvilly, R., Fong, J., Silversides, C., Chow, E., & Bassett, A. (2010). Elevated prevalence of generalized anxiety disorder in adults with 22q11. 2 deletion syndrome. *American Journal of Psychiatry*, 167(8), 998-998.

Gill, K.E., Poe, L., Azimov, N., Ben-David, S., Vadhan, N.P., Girgis, R., Moore, H., Cressman, V., Corcoran, C.M., 2015. Reasons for cannabis use among youths at ultra high risk for psychosis. *Early Interv. Psychiatry* 9 (3), 207–210. <https://doi.org/10.1111/eip.12112>.

Green T, Gothelf D, Glaser B, Debbane M, Frisch A, Kotler M, et al. Psychiatric Disorders and Intellectual Functioning Throughout Development in Velocardiofacial (22q11.2 Deletion) Syndrome. *J Am Acad Child Adolesc Psychiatry*. 2009;48:1060–8

- Grothues, J. M., Bischof, G., Reinhardt, S., Meyer, C., John, U., & Rumpf, H. J. (2008). Effectiveness of brief alcohol interventions for general practice patients with problematic drinking behavior and comorbid anxiety or depressive disorders. *Drug and alcohol dependence*, 94(1-3), 214-220
- Gunasekera, B., Diederer, K., & Bhattacharyya, S. (2021). Cannabinoids, reward processing, and psychosis. *Psychopharmacology*, 1-21.
- Hall, W., & Degenhardt, L. (2008). Cannabis use and the risk of developing a psychotic disorder. *World Psychiatry*, 7(2), 68.
- Hammond, C. J., Chaney, A., Hendrickson, B., & Sharma, P. (2020). Cannabis use among US adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates. *International review of psychiatry*, 32(3), 221-234.
- Hasin, D., & Walsh, C. (2020). Cannabis use, cannabis use disorder, and comorbid psychiatric illness: a narrative review. *Journal of Clinical Medicine*, 10(1), 15.
- Hasan, A., von Keller, R., Friemel, C. M., Hall, W., Schneider, M., Koethe, D., ... & Hoch, E. (2020). Cannabis use and psychosis: a review of reviews. *European archives of psychiatry and clinical neuroscience*, 270(4), 403-412.
- Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. *JAMA Psychiatry*. 2014;71(3):248-254. PMID: 24382686.

Henquet, C., Di Forti, M., Morrison, P., Kuepper, R., & Murray, R. M. (2008). Gene-environment interplay between cannabis and psychosis. *Schizophrenia bulletin*, 34(6), 1111-1121.

Howes, O. D., Hird, E. J., Adams, R. A., Corlett, P. R., & McGuire, P. (2020). Aberrant salience, information processing, and dopaminergic signaling in people at clinical high risk for psychosis. *Biological psychiatry*, 88(4), 304-314.

Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. *Drug and alcohol dependence*, 191, 234-258.

Jolin, E. M., Weller, R. A., Jessani, N. R., Zackai, E. H., McDonald-McGinn, D. M., & Weller, E. B. (2009). Affective disorders and other psychiatric diagnoses in children and adolescents with 22q11.2 Deletion Syndrome. *Journal of affective disorders*, 119(1-3), 177-180

Jonas RK, Montoyo CA, Bearden CE. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. *Biol Psychiatry*. 2014 Mar 1;75(5):351-60. doi: 10.1016/j.biopsych.2013.07.019. Epub 2013 Aug 28

Kalyva, E. (2007). Prevalence and influences on self-reported smoking among adolescents with mild learning disabilities, attention deficit hyperactivity disorder, and their typically developing peers. *Journal of Intellectual Disabilities*, 11(3), 267-279.

Karcher, N. R., Martin, E. A., & Kerns, J. G. (2015). Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks. *Journal of Abnormal Psychology*, 124(3), 507.

Keefe, K. (1994). Perceptions of normative social pressure and attitudes toward alcohol use: changes during adolescence. *Journal of studies on alcohol*, 55(1), 46-54.

Keough, M. T., O'Connor, R. M., Sherry, S. B., & Stewart, S. H. (2015). Context counts: Solitary drinking explains the association between depressive symptoms and alcohol-related problems in undergraduates. *Addictive behaviors*, 42, 216-221

Khokhar, J. Y., Dwiell, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018). The link between schizophrenia and substance use disorder: A unifying hypothesis. *Schizophrenia research*, 194, 78-85.

Kirkpatrick, B., Messias, E. M., & Tek, C. (2003). Substance abuse and the heterogeneity of schizophrenia: A population-based study

Kristensen K, Cadenhead KS (2007). Cannabis abuse and risk for psychosis in a prodromal sample. *Psychiatry Research* 151, 151–154.

Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. *BMJ* 342, d738.

Kuther, T. L., & Higgins-D'Alessandro, A. (2003). Attitudinal and normative predictors of alcohol use by older adolescents and young adults. *Journal of drug education*, 33(1), 71-90.

Lin A, Vajdi A, Kushan-Wells L, Helleman G, Hansen LP, Jonas RK, et al. Reciprocal Copy Number Variations at 22q11.2 Produce Distinct and Convergent Neurobehavioral Impairments

Relevant for Schizophrenia and Autism Spectrum Disorder. *Biol Psychiatry* [Internet]. Elsevier Inc; 2020;88:260–72.

Lowe, D.J.E., Sasiadek, J.D., Coles, A.S., George, T.P., 2019. Cannabis and mental illness: a review. *Eur. Arch. Psychiatry Clin. Neurosci.* 269 (1), 107–120.

Malhotra D, Sebat J. CNVs: Harbingers of a rare variant revolution in psychiatric genetics. *Cell*. Elsevier Inc.; 2012;148:1223–41. Available from: <http://dx.doi.org/10.1016/j.cell.2012.02.039>. 20.

Marconi, A., Di Forti, M., Lewis, C.M., Murray, R.M., Vassos, E., 2016. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr. Bull.* 42 (5), 1262–1269.

Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet.* 2017;49:27–35.

Martin, A. K., Robinson, G., Reutens, D., & Mowry, B. (2014). Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. *Schizophrenia research*, 155(1-3), 21-25

Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behav Res Ther* 1998; 36: 455–470.

McGlashan TH, Walsh BC, Woods SW (2010). The Psychosis Risk Syndrome: Handbook for Diagnosis and Follow-up. Oxford University Press: New York.

McGue, M., Gottesman, I. I., & Rao, D. C. (1983). The transmission of schizophrenia under a multifactorial threshold model. *American Journal of Human Genetics*, 35(6), 1161

McGuffin, P. (2004). Nature and nurture interplay: schizophrenia. *Psychiatrische Praxis*, 31(S 2), 189-193

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* 370, 319–328.

Mueser, K. T., Yarnold, P. R., Rosenberg, S. D., Swett Jr, C., Miles, K. M., & Hill, D. (2000). Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. *Schizophrenia bulletin*, 26(1), 179-192.

Mustonen, A., Niemela, S., Nordstro, T., Murray, G.K., Ma, ki, P., J, ä, askela, inen, E., Miettunen, J., 2018. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. *Br. J. Psychiatry* 212 (4), 227–233.

Olsen L, Sparsø T, Weinsheimer SM, Dos Santos MBQ, Mazin W, Rosengren A, et al. Prevalence of rearrangements in the 22q11.2 region and population-based risk of

neuropsychiatric and developmental disorders in a Danish population: a case-cohort study. *The Lancet Psychiatry*. 2018;5:573–80.

RachBeisel, J., Scott, J., & Dixon, L. (1999). Co-occurring severe mental illness and substance use disorders: a review of recent research. *Psychiatric services*, 50(11), 1427-1434.

Rais, M., Cahn, W., Van Haren, N., Schnack, H., Caspers, E., Hulshoff Pol, H., & Kahn, R. (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. *American Journal of Psychiatry*, 165(4), 490-496.

Rao, U. (2006). Links between depression and substance abuse in adolescents: neurobiological mechanisms. *American journal of preventive medicine*, 31(6), 161-174.

Realini, N., Vigano, D., Guidali, C., Zamberletti, E., Rubino, T., & Parolaro, D. (2011). Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. *Neuropharmacology*, 60(2-3), 235-243.

Rees E, Kendall K. Europe PMC Funders Group Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. 2017;73:963–9. 23.

Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA* 264, 2511–2518.

Rimvall, M. K., van Os, J., Rask, C. U., Olsen, E. M., Skovgaard, A. M., Clemmensen, L., ... & Jeppesen, P. (2020). Psychotic experiences from preadolescence to adolescence: when should we be worried about adolescent risk behaviors?. *European Child & Adolescent Psychiatry*, 29(9), 1251-1264.

Santesteban-Echarri, O., Liu, L., Miller, M., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., ... & Addington, J. (2022). Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis. *Schizophrenia Research*, 248, 114-121.

Schifani, C., Tseng, H.-H., Rao, N., Wilson, A.A., Houle, S., Rusjan, P.M., Pruessner, J., Tagore, A., Mizrahi, R., 2020. Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. *Addict. Biol.* 25 (4), e12812.

Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, Van Den Bree MBM, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: Results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. *Am J Psychiatry*. 2014;171:627–39.

Schoeler, T., Monk, A., Sami, M.B, Klamerus, E., Foglia, E., Brown, R., Camuri, G., Altamura, A.C., Murray, R., Bhattacharyya, S., 2016. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. *Lancet Psychiatry* 3, 215–225.

Smith, J. P., & Book, S. W. (2008). Anxiety and substance use disorders: A review. *The Psychiatric Times*, 25(10), 19.

Stevenson, J., Miller, C. L., Martin, K., Mohammadi, L., & Lawn, S. (2022). Investigating the reciprocal temporal relationships between tobacco consumption and psychological disorders for youth: an international review. *BMJ open*, *12*(6), e055499.

Swerts, C., Vandeveld, S., VanDerNagel, J. E., Vanderplasschen, W., Claes, C., & De Maeyer, J. (2017). Substance use among individuals with intellectual disabilities living independently in Flanders. *Research in developmental disabilities*, *63*, 107-117.

Swillen, A., & McDonald-McGinn, D. (2015, June). Developmental trajectories in 22q11. 2 deletion syndrome. In *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* (Vol. 169, No. 2, pp. 172-181).

Thornton LK, Baker AL, Johnson MP, Kay-Lambkin F, Lewin TJ (2012). Reasons for substance use among people with psychotic disorders: method triangulation approach. *Psychology of Addictive Behaviors* *26*, 279–288.

Tsuang, M. T., Stone, W. S., & Faraone, S. V. (2001). Genes, environment and schizophrenia. *The British Journal of Psychiatry*, *178*(S40), s18-s24

J van der Meer, F., Velthorst, E., J Meijer, C., WJ Machielsen, M., & de Haan, L. (2012). Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Current pharmaceutical design*, *18*(32), 5036-5044.

van Duijvenbode, N., VanDerNagel, J. E., Didden, R., Engels, R. C., Buitelaar, J. K., Kiewik, M., & de Jong, C. A. (2015). Substance use disorders in individuals with mild to borderline intellectual disability: current status and future directions. *Research in Developmental Disabilities, 38*, 319-328.

van Duin, EDA, Goossens, L, Hernaes, D, da Silva Alves, F, Schmitz, N, Schruers, K, et al. Neural correlates of reward processing in adults with 22q11 deletion syndrome. *J Neurodev Disord* 2016; 8: 25.

van Nimwegen, L., De Haan, L., Van Beveren, N., Van Den Brink, W., & Linszen, D. (2005). Adolescence, schizophrenia and drug abuse: a window of vulnerability. *Acta Psychiatrica Scandinavica, 111*, 35-42.

Vingerhoets, C., Van Oudenaren, M. J., Bloemen, O. J., Boot, E., Van Duin, E. D., Evers, L. J., ... & Outcome of Psychosis (GROUP) Investigators. (2019). Low prevalence of substance use in people with 22q11.2 deletion syndrome. *The British Journal of Psychiatry, 215*(5), 661-667.

Volkow, ND. Substance use disorders in schizophrenia--clinical implications of comorbidity. *Schizophr Bull* 2009; 35(3): 469-72

Waltz, J., Demro, C., Schiffman, J., Thompson, E., Kline, E., Reeves, G., ... & Gold, J. (2015). Reinforcement learning performance and risk for psychosis in youth. *The Journal of nervous and mental disease, 203*(12), 919.

Ward, H. B., Lawson, M. T., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., ... & Perkins, D. O. (2019). Tobacco use and psychosis risk in persons at clinical high risk. *Early intervention in psychiatry*, 13(5), 1173-1181

Whitesell, M., Bachand, A., Peel, J., & Brown, M. (2013). Familial, social, and individual factors contributing to risk for adolescent substance use. *Journal of addiction*, 2013.

Wilson, J., Freeman, T. P., & Mackie, C. J. (2019). Effects of increasing cannabis potency on adolescent health. *The Lancet Child & Adolescent Health*, 3(2), 121-128.

Young, SE, Corley, RP, Stallings, MC, Rhee, SH, Crowley, TJ, Hewitt, JK. Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. *Drug Alcohol Depend* 2002; 68(3): 309–22

Zung, W. W. (1971). Self-rating anxiety scale. *BMC Psychiatry*

J van der Meer, F., Velthorst, E., J Meijer, C., WJ Machielsen, M., & de Haan, L. (2012).

Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. *Current pharmaceutical design*, 18(32), 5036-5044.

van Duin, EDA, Goossens, L, Hernaus, D, da Silva Alves, F, Schmitz, N, Schruers, K, et al. Neural correlates of reward processing in adults with 22q11 deletion syndrome. *J Neurodev Disord* 2016; 8: 25.

van Nimwegen, L., De Haan, L., Van Beveren, N., Van Den Brink, W., & Linszen, D. (2005).

Adolescence, schizophrenia and drug abuse: a window of vulnerability. *Acta Psychiatrica*

Scandinavica, 111, 35-42.

Vingerhoets, C., Van Oudenaren, M. J., Bloemen, O. J., Boot, E., Van Duin, E. D., Evers, L. J.,

... & Outcome of Psychosis (GROUP) Investigators. (2019). Low prevalence of substance use in

people with 22q11. 2 deletion syndrome. *The British Journal of Psychiatry*, 215(5), 661-667.

Volkow, ND. Substance use disorders in schizophrenia--clinical implications of comorbidity.

Schizophr Bull 2009; 35(3): 469-72

Waltz, J., Demro, C., Schiffman, J., Thompson, E., Kline, E., Reeves, G., ... & Gold, J. (2015).

Reinforcement learning performance and risk for psychosis in youth. *The Journal of nervous*

and mental disease, 203(12), 919.

Whitesell, M., Bachand, A., Peel, J., & Brown, M. (2013). Familial, social, and individual factors

contributing to risk for adolescent substance use. *Journal of addiction*, 2013.

Wilson, J., Freeman, T. P., & Mackie, C. J. (2019). Effects of increasing cannabis potency on

adolescent health. *The Lancet Child & Adolescent Health*, 3(2), 121-128.

Young, SE, Corley, RP, Stallings, MC, Rhee, SH, Crowley, TJ, Hewitt, JK. Substance use,

abuse and dependence in adolescence: prevalence, symptom profiles and correlates. *Drug*

Alcohol Depend 2002; 68(3): 309-22

Zung, W. W. (1971). Self-rating anxiety scale. BMC Psychiatry